Oncternal Therapeutics Inc (ONCT)

NASDAQ
6.47
+0.34(+5.55%)
  • Volume:
    1,073,006
  • Bid/Ask:
    6.45/6.47
  • Day's Range:
    6.15 - 6.55

ONCT Overview

Prev. Close
6.13
Day's Range
6.15 - 6.55
Revenue
3.37M
Open
6.2
52 wk Range
1.49 - 10.54
EPS
-0.95
Volume
1,073,006
Market Cap
302.6M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,680,161
P/E Ratio
N/A
Beta
1.64
1-Year Change
118.93%
Shares Outstanding
49,363,841
Next Earnings Date
May 13, 2021
What is your sentiment on Oncternal Therapeutics Inc?
or
Vote to see community's results!

Oncternal Therapeutics Inc News

Oncternal Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralSellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellBuy
SummaryStrong BuyStrong BuyBuyStrong SellNeutral

Oncternal Therapeutics Inc Company Profile

Oncternal Therapeutics Inc Company Profile

Employees
12

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Read More
  • This one could be yummy
    0
    • But, I'm surprised NOW.
      0
      • Won't be surprised if ONCT hit $4 before end of January 2021.
        0
        • WHAT'S UP. Why dropped so much AH?😅
          0
          • why drop ?
            0
            • wow, pending defence deal.
              1
              • they way overvalued for a research company. they got no revenue.
                0
                • I'm in for 1K shares @1.77...should get to $3-4 imo short term.
                  1
                  • The news said their only product tanked in trial. Not whole true. 2 more cancer meds in the works, the trial was not terrible, just inconclusive. Does not = an 80% drop to me. I'm buying in to a rebound.
                    0
                    • I had the sane thought buy now while its down. I heard they're in trial for Prostate cancer research now..
                      0
                  • Yes me !
                    0
                    • Anyone else interested in this ?
                      0
                      • What do you think happens next week?
                        0
                      • Not really sure wondering that myself
                        0
                      • I see a break through coming.
                        0
                    • Id say great tune to buy it went down way too fast lol had too @billsmith
                      1
                      • I think there is high potential for this stock to rebound
                        0
                        • should we buy?
                          0
                          • should we buy?
                            0
                            • Great time to short up to fast
                              0
                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.